Skip to main content

The Development of Medications for the Treatment of Opiate and Cocaine Addictions Issues for the Government and Private Sector (1995) / Chapter Skim
Currently Skimming:

Appendix G: Health Care Reform Legislation
Pages 242-247

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 242...
... tion drug rebates; . the inclusion of drug abuse treatment benefits, and the extent to which these benefits are restricted, managed, or treated relative to other medical benefits; · the nature of additional insurance reform, such as eliminating exclusions for preexisting conditions; .
Read the entire page →
From page 243...
... If coverage were extended to more of the uninsured, especially to those who are drug dependent, the effect would likely benefit investment in anti-addiction medications, as long as the insurance benefits are at least partially tailored to the needs of that group. Greater insurance coverage means a shift from the public funding system (primarily from block grants arid state alcohol alla drug agencies)
Read the entire page →
From page 244...
... A generous benefit would almost certainly attract more pharmaceutical investment, but because of the inability to forecast the extent of costs, benefits are generally limited to brief interventions and short-term treatment. The Health Security Act, for example, proposed coverage for up to 30 days in residential treatment or 60 days in day treatment and up to 30 outpatient psychotherapy Prescription drug manufacturers are required to rebate state Medicaid programs for their prescription drug purchases under the Medicaid Rebate Law, passed as part of the Omnibus Budget Reconciliation Act of 1990 (P.L.
Read the entire page →
From page 245...
... Should the benefit structure of future legislation create incentives to seek primary care instead of specialty care for treatment of drug dependence, primary care physicians will need additional training in addiction medicine. In light of the movement toward increased reliance on primary care physicians for diagnosis and treatment of all medical conditions, the committee strongly supports increased training in addiction medicine for primary care providers (Chapter 6~.
Read the entire page →
From page 246...
... It will depend on the extent to which current Medicaid recipients purchase subsidized private insurance or are relegated to the public treatment system. Additionally, the imposition of government price controls to reduce the costs of health care is inimical to the pharmaceutical industry.
Read the entire page →
From page 247...
... 1994. How Health Care Reform Affects Pharmaceutical Research and Development.
Read the entire page →

Key Terms

  • drug abuse
  • abuse treatment
  • insurance coverage
  • care reform
  • pharmaceutical companies

  • health insurance
  • drug benefit
  • private insurance
  • treatment benefits
  • medical conditions

  • pharmaceutical investment
  • pharmaceutical research
  • antiaddiction medications
  • public subsidies
  • future legislation

  • pharmaceutical revenues
  • medicaid spending
  • relapsing medical
  • care physicians
  • direct effect

  • direct public
  • medicare rebate
  • addiction medicine
  • pharmaceutical industry
  • increase pharmaceutical

  • medicare population
  • benefit structure
  • drug agencies
  • public sector
  • drug manufacturers


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.